SCHEMBL15412955

SCHEMBL15412955

CCOc1ccn(-c2ccc(F)cc2C)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 5/20 0.43
GRIN1 Q05586 5/20 0.43
GRIN2B Q13224 5/20 0.43
ATP4A P20648 2/20 0.38
ATP4B P51164 2/20 0.38
CRHR1 P34998 2/20 0.37
HCAR1 Q9BXC0 1/20 0.36
AURKA O14965 1/20 0.35
ABL1 P00519 1/20 0.35
LCK P06239 1/20 0.35
MET P08581 1/20 0.35
SRC P12931 1/20 0.35
FER P16591 1/20 0.35
AXL P30530 1/20 0.35
CDK8 P49336 1/20 0.35
TYRO3 Q06418 1/20 0.35
MERTK Q12866 1/20 0.35
MAP2K5 Q13163 1/20 0.35
AURKB Q96GD4 1/20 0.35
HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20001815 0.79 RXRA (0.39) RXRAGRIN1GRIN2BHTTALDH1A1
SCHEMBL15412947 0.77 KDM4E (0.44) HTTKMT2APTGS2SIGMAR1LMNA
SCHEMBL16201981 0.77 MAPT (0.53) RXRAGRIN1GRIN2BCRHR1HCAR1
SCHEMBL23749443 0.76 KDM4E (0.44) RXRAGRIN1GRIN2BMEN1GABRP
SCHEMBL30030622 0.76 KDM4E (0.44) RXRAGRIN1GRIN2BMEN1GABRP
SCHEMBL20249708 0.74 CRHR1 (0.40) RXRAGRIN1GRIN2BCRHR1HCAR1
SCHEMBL164750 0.72 HTR7 (0.43) RXRAGRIN1GRIN2BAURKAABL1
SCHEMBL167624 0.70 AURKA (0.52) RXRAGRIN1GRIN2BATP4AATP4B
SCHEMBL164749 0.70 AURKA (0.51) RXRAGRIN1GRIN2BATP4AATP4B
SCHEMBL166572 0.70 AURKA (0.51) RXRAGRIN1GRIN2BATP4AATP4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8999982-B2 Pharmaceutically active compounds as Axl inhibitors LEAD DISCOVERY CENTER GMBH (DE) 2015-04-07 US disclosed
US-20140018365-A1 PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCCHAFTEN E.V. (DE) 2014-01-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140018365-A1 PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS AXL, FLT3, ERBB3 RXRA 2266/4885GRIN1 1102/4885GRIN2B 1683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.